<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2018.8389</article-id>
<article-id pub-id-type="publisher-id">mmr-17-03-4791</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Anti-inflammatory effects of gambogic acid in murine collagen-induced arthritis through PI3K/Akt signaling pathway</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qing Lai</given-names></name>
<xref rid="af1-mmr-17-03-4791" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Dong Zhen</given-names></name>
<xref rid="af1-mmr-17-03-4791" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Lv</surname><given-names>Cunxian</given-names></name>
<xref rid="af1-mmr-17-03-4791" ref-type="aff"/>
<xref rid="c1-mmr-17-03-4791" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-mmr-17-03-4791">Department of Traditional Chinese Medicine Orthopaedics, Chinese Traditional Medicine Hospital of Wenzhou, Wenzhou, Zhejiang 325000, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-17-03-4791"><italic>Correspondence to</italic>: Mr Cunxian Lv, Department of Traditional Chinese Medicine Orthopaedics, Chinese Traditional Medicine Hospital of Wenzhou, 9 Jiaowei Road, Wenzhou, Zhejiang 325000, P.R. China, E-mail: <email>lwef70004114@126.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>03</month><year>2018</year></pub-date>
<pub-date pub-type="epub"><day>08</day><month>01</month><year>2018</year></pub-date>
<volume>17</volume>
<issue>3</issue>
<fpage>4791</fpage>
<lpage>4796</lpage>
<history>
<date date-type="received"><day>29</day><month>03</month><year>2017</year></date>
<date date-type="accepted"><day>05</day><month>09</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2018, Spandidos Publications</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<abstract>
<p><italic>Garcinia angustifolia</italic> is a dry resin secreted by <italic>Garcinia cambogia</italic>, which has the functions of breaking blood, detoxifying, stopping bleeding and killing insects. It is used for the treatment of cancer and brain edema. Gambogic acid is the primary active ingredient. The present study aimed to investigate the anti-inflammatory and antiproliferative effects of gambogic acid on arthritis and the possible mechanisms. It was demonstrated that gambogic acid decreased arthritic scores in murine collagen-induced arthritic mice. The tumor necrosis factor (TNF)-&#x03B1;, interleukin (IL)-1&#x03B2;, IL-6 and IL-18 concentrations, and caspase-3 and caspase-9 were significantly inhibited by gambogic acid in arthritic mice. Gambogic acid decreased matrix metalloproteinases (MMP)-2, MMP-9, nuclear factor (NF)-&#x03BA;B and phosphorylated-p38 protein expression, and increased tissue inhibitors of matrix metalloproteases-1 (TIMP-1) protein expression in arthritic mice. Furthermore, the phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (Akt) signaling pathway was induced in arthritic mice treated with gambogic acid. The results suggested that gambogic acid induced anti-inflammatory effects in murine collagen-induced arthritis, through the PI3K/Akt signaling pathway, and offers future potential for application in arthritis patients.</p>
</abstract>
<kwd-group>
<kwd>gambogic acid</kwd>
<kwd>arthritis</kwd>
<kwd>PI3K/Akt</kwd>
<kwd>anti-inflammatory effects</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by polyarticularsynovitis (<xref rid="b1-mmr-17-03-4791" ref-type="bibr">1</xref>). Its autoantigen is not organ-specific, but a common component of many organs and tissues, such as nucleus, mitochondria and so on, so it can cause the damage of multiple organs and multiple tissues (<xref rid="b2-mmr-17-03-4791" ref-type="bibr">2</xref>). Epidemiological survey shows that in China, the incidence rate of RA is 0.32&#x2013;0.38&#x0025;, while in Europe, the United States and Africa, it is up to 0.5&#x2013;2.0&#x0025;. Its pathogenesis is complex, influenced by genetic and environmental factors (<xref rid="b3-mmr-17-03-4791" ref-type="bibr">3</xref>). As the patients with RA have high disability rate, it brings a great financial burden to the patients themselves and the whole community, which has becomethe hot topic during the last 10 years for domestic and foreign scholars (<xref rid="b3-mmr-17-03-4791" ref-type="bibr">3</xref>). The basic pathologic changes of RA are synovial cell hyperplasia, thickening of lining layer, infiltration of multiple inflammatory cells, pannus formation and destruction of cartilage and bone tissue, eventually leading to joint deformity and loss of function (<xref rid="b4-mmr-17-03-4791" ref-type="bibr">4</xref>).</p>
<p>RA is related to the signal transduction pathways of multiple cytokines. In recent years, it has been found that phosphoinositide 3 kinase (PI3K)/protein kinase B (PKB) signaling pathway (PI3K/Akt pathway) is involved in a very rapid signal transduction system from the membrane to the nuclear and its downstream pathways Bad, caspase and nuclear factor (NF)-&#x03BA;B are important pathways affecting osteoarthritis (<xref rid="b5-mmr-17-03-4791" ref-type="bibr">5</xref>). Recent studies have shown that the signal transduction pathway ofkinase plays an important role in the process of chondrocyte apoptosis (<xref rid="b5-mmr-17-03-4791" ref-type="bibr">5</xref>,<xref rid="b6-mmr-17-03-4791" ref-type="bibr">6</xref>).</p>
<p>PI3K/Akt/mTOR signal pathway plays an important role in the proliferation and survivalof lymphocyte (<xref rid="b7-mmr-17-03-4791" ref-type="bibr">7</xref>). However, the literature has shown that PI3K/Akt/mTOR signal transduction pathway isstudied in the pathological mechanisms and treatment methods of malignant tumors. mTOR and PI3K signals play an important role in regulation of B lymphocyte morphology, metabolic activity, and cell cycle progression (<xref rid="b8-mmr-17-03-4791" ref-type="bibr">8</xref>).</p>
<p>Gamboge is adry resinsecreted by Garcinia plant, <italic>Garcinia hanbaryi</italic> Hook. f. It is produced mainly in Cambodia, India, Thailand and Vietnam, as well as Guangdong and Hainan in China (<xref rid="b9-mmr-17-03-4791" ref-type="bibr">9</xref>). It has been documented for a long time in our traditional medicine, as Garcinia cold, Pickle, Sim, astringent, toxic, with the functions of breaking blood, detoxifying, stopping bleeding and killing insects, which has been used for the treatment of crewels, scrofulaceum, and carbuncle, since ancient times (<xref rid="b10-mmr-17-03-4791" ref-type="bibr">10</xref>). It contains gambogic acid, neogambogic acid, allogambogic acid, morellin, isomorellin, morellic acid, isomorellic acid and so on, in which gambogic acid is the main active ingredient. Gambogic acid (<xref rid="f1-mmr-17-03-4791" ref-type="fig">Fig. 1</xref>) has anti-inflammatory, antioxidation and anticancer effects (<xref rid="b11-mmr-17-03-4791" ref-type="bibr">11</xref>,<xref rid="b12-mmr-17-03-4791" ref-type="bibr">12</xref>). Ma <italic>et al</italic> (<xref rid="b13-mmr-17-03-4791" ref-type="bibr">13</xref>) showed that gambogic acid inhibits osteoclast formation and ovariectomy-induced osteoporosis. The purpose of this study is for the first time to elucidate the anti-inflammatory and antiproliferative effects of gambogic acid on arthritis and the possible mechanisms.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Animals and treatment</title>
<p>Collagen-induced arthritis in mice was a common RA model using collagen II. Male DBA/1 mice (5-week-old) was purchased from Wenzhou Laboratory Animal Center (Wenzhou, China) and kept in specific pathogen-free conditions in Animal Center of Wenzhou Medical University. This study gained ethical approval from Chinese Traditional Medicine (Wenzhou, China). Arthritis was induced and emulsified in complete Freund&#x0027;s adjuvant and injected intradermally into the tail with 200 &#x00B5;g of collagen II (<xref rid="b14-mmr-17-03-4791" ref-type="bibr">14</xref>). Meanwhile, in treatment with gambogic acid group, mice were treatment with 2 mg/kg/3 day (intraperitoneal injection) for 28 days (<xref rid="b15-mmr-17-03-4791" ref-type="bibr">15</xref>). All mice were randomly assigned into three groups: Sham group, RA model group and GA group; amount of very group is 10 mice.</p>
</sec>
<sec>
<title>ELISA analyzing</title>
<p>Serum from very mice after treatment with gambogic acid at 28 days was collected and centrifuged at 1,500 g for 10 min. Serum was used to analyze inflammation factors [tumor necrosis factor (TNF)-&#x03B1;, interleukin (IL)-1&#x03B2;, IL-6 and IL-18 concentrations] using ELISA kits (Nanjing Jiancheng Biology Engineering Institute, Nanjing, China).</p>
<p>Then, tissue extracts were prepared from very mice after treatment with gambogic acid at 28 days and extracted using RIPA assay. Tissue extracts were prepared after treatment with gambogic acid at 28 days and extracted using RIPA assay. Protein quantified was measured using BCA assay. Briefly, proteins were used to analyze caspase-3 and caspase-9 activity using Commercial ELISA kits (Nanjing Jiancheng Biology Engineering Institute).</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Tissue extracts were prepared after treatment with gambogic acid at 28 days and extracted using RIPA assay. Protein quantified was measured using BCA assay. Briefly, proteins were size fractionated by 8&#x2013;12&#x0025; sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane. The following antibodies were employed with matrix metalloproteinases (MMP)-2, MMP-9, NF-&#x03BA;B, phosphorylated (p-)p38, tissue inhibitors of matrix metalloproteases-1 (TIMP-1), PI3K, p-Akt and GAPDH (Santa Cruz Biotechnology Inc., Milan, Italy) at 4&#x00B0;C overnight. Secondary anti-mouse IgG peroxidase conjugate was used to incubate for 1 h at 37&#x00B0;C. Detection was carried out with ECL Fast Pico (ECL-1002; Immunological Sciences, Rome, Italy) and quantified the ImageJ software system and Alliance LD (Uvitec, Cambridge, UK).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The data of statistical analysis are presented as mean &#x00B1; SD and were compared by two-way analysis of variance with a Sidak&#x0027;s multiple comparison test post hoc. P-value &#x003C;0.05 considered to be statistically significant.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Gambogic acid decreases arthritis scores in RA mice</title>
<p>To examine whether the effects of gambogic acid on arthritis, we recorded arthritis scores in RA mice by gambogic acid. As showed in <xref rid="f1-mmr-17-03-4791" ref-type="fig">Fig. 1</xref>, a significant increase of arthritis scores in RA model mice. However, gambogic acid inhibited arthritis scores at 21 or 28 days in RA mice (<xref rid="f2-mmr-17-03-4791" ref-type="fig">Fig. 2</xref>).</p>
</sec>
<sec>
<title>Gambogic acid decreases TNF-&#x03B1;, IL-1&#x03B2;, IL-6 and IL-18 concentrations in RA mice</title>
<p>To investigate the anti-inflammation effects of gambogic acid on RA, TNF-&#x03B1;, IL-1&#x03B2;, IL-6 and IL-18 concentrations were measured using ELISA KITS. <xref rid="f3-mmr-17-03-4791" ref-type="fig">Fig. 3</xref> showed that TNF-&#x03B1;, IL-1&#x03B2;, IL-6 and IL-18 concentrations in RA model mice were significantly increased, compared with control group. These inflammation factors were significantly reduced in RA mice by gambogic acid for 28 days (<xref rid="f3-mmr-17-03-4791" ref-type="fig">Fig. 3</xref>).</p>
</sec>
<sec>
<title>Gambogic acid decreases caspase-3 and caspase-9 activity in RA mice</title>
<p>To assess the involvement of caspases for cell apoptosis of RA treated by gambogic acid, caspase-3 and caspase-9 activity were analyzed using ELISA kits. As showed that caspase-3 and caspase-9 activity of RA model was higher than those of control group (<xref rid="f4-mmr-17-03-4791" ref-type="fig">Fig. 4</xref>). The high level of caspase-3 and caspase-9 activity in RA model reduced by gambogic acid, compared with RA model group (<xref rid="f4-mmr-17-03-4791" ref-type="fig">Fig. 4</xref>).</p>
</sec>
<sec>
<title>Gambogic acid decreases MMP-2 and MMP-9 protein expression in RA mice</title>
<p>Then, we analyzed MMP-2 and MMP-9 protein expression treated by gambogic acid. The result of <xref rid="f5-mmr-17-03-4791" ref-type="fig">Fig. 5</xref> showed that RA induced MMP-2 and MMP-9 protein expression in mice model, compared with control group. Certainly, gambogic acid significantly inhibited MMP-2 and MMP-9 protein expression in RA model group, compared with RA model group (<xref rid="f5-mmr-17-03-4791" ref-type="fig">Fig. 5</xref>).</p>
</sec>
<sec>
<title>Gambogic acid decreases NF-&#x03BA;B and p-p38 protein expression in RA mice</title>
<p>To understand the anti-inflammation mechanism of gambogic acid on RA, NF-&#x03BA;B and p-p38 protein expression were measured using western blot analysis. As showed in <xref rid="f6-mmr-17-03-4791" ref-type="fig">Fig. 6</xref>, NF-&#x03BA;B and p-p38 protein expression were significantly induced in RA, model group, compared with control group. Treatment with gambogic acid significantly suppressed NF-&#x03BA;B and p-p38 protein expression in RA mice, exhibited that gambogic acid inhibited inflammation in RA mice through NF-&#x03BA;B and p-p38 protein expression (<xref rid="f6-mmr-17-03-4791" ref-type="fig">Fig. 6</xref>).</p>
</sec>
<sec>
<title>Gambogic acid increases PI3K/Akt singnaling pathway in RA mice</title>
<p>Furthermore, to investigate the anti-apoptosis mechanism of gambogic acid on RA, TIMP-1 and PI3K/Akt singnaling pathway were selected and analyzed in this study. <xref rid="f7-mmr-17-03-4791" ref-type="fig">Fig. 7</xref> showed that TIMP-1 and PI3K/Akt singnaling pathway were suppressed in RA model group, compared with control group. Gambogic acid could promote TIMP-1 and PI3K/Akt singnaling pathway in RA mice. These data illuminated that gambogic acid alleviated cell apoptosis in RA through TIMP-1 and PI3K/Akt singnaling pathway.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>RA is a systemic inflammatory autoimmune disease related to the involvement of the surrounding joints, which is characterized by inflammation of the synovial tissue and progressive destruction of the joints (<xref rid="b16-mmr-17-03-4791" ref-type="bibr">16</xref>). Cytokine TNF-&#x03B1; plays an important role in synovial inflammation and bone destruction of RA (<xref rid="b17-mmr-17-03-4791" ref-type="bibr">17</xref>). It is suggested that TNF-&#x03B1; induces synovial cells to produce the expressions of many inflammatory cytokines (such as IL-6 and IL-8) and collagenase (MMP), which is a key factor for the persistence and progression of RA (<xref rid="b18-mmr-17-03-4791" ref-type="bibr">18</xref>). In our study, gambogic acid inhibited arthritis scores, and TNF-&#x03B1;, IL-1&#x03B2;, IL-6 and IL-18 concentrations in RA mice. Wen <italic>et al</italic> (<xref rid="b15-mmr-17-03-4791" ref-type="bibr">15</xref>) suggested that gambogic acid exhibits anti-psoriatic efficacy through inhibition of inflammation.</p>
<p>NF-&#x03BA;B signal pathway plays an important role in the inflammatory process of RA (<xref rid="b19-mmr-17-03-4791" ref-type="bibr">19</xref>). The transcription factor, NF-&#x03BA;B may play an important role in the pathogenesis of infectious diseases and autoimmune diseases by regulating the expression of various cytokines and cell adhesion molecules (<xref rid="b6-mmr-17-03-4791" ref-type="bibr">6</xref>). The activated transcription factor, NF-&#x03BA;B, binds to the &#x03BA;B site in the promoter region of the corresponding inflammatory mediator target gene, leading to the over-expression of the inflammatory mediator gene (<xref rid="b20-mmr-17-03-4791" ref-type="bibr">20</xref>). In recent years, we have found that NF-&#x03BA;B is activated in RA synovial tissue abnormally, and the NF-&#x03BA;B pathway in RA synovial tissue and synovial fluid regulates the expression of many inflammatory cytokines, such as cytokines (TNF-&#x03B1;, IL-1, IL-6, IL-2, IL-12, IFN-&#x03B3;), adhesion molecules (VCAM-1, ICAM-1), chemokines (IL-8, MIP-1&#x03B1;, MCP-1, TIMP-1), and MMPs (MMP-1, MMP-3, MMP-13) (<xref rid="b21-mmr-17-03-4791" ref-type="bibr">21</xref>). And we also found that treatment with gambogic acid significantly suppressed NF-&#x03BA;B and MMP-2 and MMP-9 protein expression in RA mice. Tang <italic>et al</italic> (<xref rid="b11-mmr-17-03-4791" ref-type="bibr">11</xref>) suggested that gambogic acid inhibits the growth of ovarian cancer tumors through RELA/NF-&#x03BA;B p65 (p65) activity. Qi <italic>et al</italic> (<xref rid="b22-mmr-17-03-4791" ref-type="bibr">22</xref>) indicated that gambogic acid suppressed lung metastasis of human breast carcinoma cell through protein kinase C (PKC) mediated MMP-2/9 expression inhibition.</p>
<p>p38 mitogen-activated protein kinase plays an important role in normal cartilage cell physiology and pathogenesis of osteoarthritis (<xref rid="b23-mmr-17-03-4791" ref-type="bibr">23</xref>). P38 can regulate the proliferation and survival of chondrocytes, balance the extracellular matrix metabolism, and play a key role in the pathogenesis of osteoarthritis cartilage degeneration induced by MMPs and proinflammatory factors (<xref rid="b24-mmr-17-03-4791" ref-type="bibr">24</xref>). Our results indicated that gambogic acid significantly suppressed p-p38 protein expression in RA mice. Ma <italic>et al</italic> (<xref rid="b13-mmr-17-03-4791" ref-type="bibr">13</xref>) demonstrated that gambogic acid inhibits osteoclast formation in p38 and Akt signalling pathways.</p>
<p>The abnormal mechanism of chondrocyte apoptosis has not been elucidated and may be related to many signal transduction pathways, in which PI3K/AKT signal transduction pathway has been considered as an important pathway of chondrocyte apoptosis (<xref rid="b25-mmr-17-03-4791" ref-type="bibr">25</xref>). PI3K is a membrane protein that can directly or indirectly activate the downstream factor AKT by accepting the afferent signals of tyrosine kinase receptors, cytokine receptors, CD19, BCR, GPCR, etc. on the membrane (<xref rid="b26-mmr-17-03-4791" ref-type="bibr">26</xref>). The biological effects of AKT include protein synthesis, anti-apoptosis, blocking the cytoplasm, regulating cell growth cycle, glucose metabolism (glycolysis, glucose conversion and glycogen synthesis) and neurodegeneration (<xref rid="b27-mmr-17-03-4791" ref-type="bibr">27</xref>). The anti-apoptotic effect of AKT is realized by the following three ways: Playing anti-apoptotic effectby XIAP factor; inhibition of Bax, Bcl-2, Bim and FOX01-induced apoptosis; isolation of Bad (14-3-3) in the cytoplasm (<xref rid="b27-mmr-17-03-4791" ref-type="bibr">27</xref>). PI3K/Akt signal is involved in the regulation of B lymphocyte proliferation and differentiation by the activation of mTOR, and mTOR is a target molecule for rapamycin, which plays a critical role in regulating cell growth and proliferation (<xref rid="b28-mmr-17-03-4791" ref-type="bibr">28</xref>). mTOR signal affects cell cycle, cell growth and cell proliferation. In many human cancers, the absence of some important tumor suppressors (PTEN, TSC1/2, LKB1) in mTOR signal pathway, cell mutations or the gene amplification in PI3CA (P110&#x03B1; subtype) and abnormalities caused by Akt activation mutations, ultimately lead to cell proliferation, cell survival and cell self-phagocytosis inhibition (<xref rid="b8-mmr-17-03-4791" ref-type="bibr">8</xref>,<xref rid="b29-mmr-17-03-4791" ref-type="bibr">29</xref>). Our data also showed that gambogic acid could promote PI3K/Akt singnaling pathway in RA mice. Wang <italic>et al</italic> (<xref rid="b30-mmr-17-03-4791" ref-type="bibr">30</xref>) identified that gambogic acid suppresses multiple myeloma cell growth through PI3K/Akt singnaling pathway.</p>
<p>In summary, this study reveals that gambogic acid prevents inflammation and apoptosis in RA model mice through NF-&#x03BA;B p65/MMP-2/9 and PI3K/Akt singnaling pathway. These findings may be valuable in the further exploration of gambogic acid in therapy for RA.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="b1-mmr-17-03-4791"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Welsing</surname><given-names>PM</given-names></name><name><surname>Woodworth</surname><given-names>TG</given-names></name><name><surname>Middelink</surname><given-names>LM</given-names></name><name><surname>Peth&#x00F6;-Schramm</surname><given-names>A</given-names></name><name><surname>Bernasconi</surname><given-names>C</given-names></name><name><surname>Borm</surname><given-names>ME</given-names></name><name><surname>Wortel</surname><given-names>CH</given-names></name><name><surname>Ter Borg</surname><given-names>EJ</given-names></name><name><surname>Jahangier</surname><given-names>ZN</given-names></name><etal/></person-group><article-title>Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): A multicentre, randomised, double-blind, double-dummy, strategy trial</article-title><source>Lancet</source><volume>388</volume><fpage>343</fpage><lpage>355</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30363-4</pub-id><pub-id pub-id-type="pmid">27287832</pub-id></element-citation></ref>
<ref id="b2-mmr-17-03-4791"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sellam</surname><given-names>J</given-names></name><name><surname>Marion-Thore</surname><given-names>S</given-names></name><name><surname>Dumont</surname><given-names>F</given-names></name><name><surname>Jacques</surname><given-names>S</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name><name><surname>Rouanet</surname><given-names>S</given-names></name><name><surname>Taoufik</surname><given-names>Y</given-names></name><name><surname>Hendel-Chavez</surname><given-names>H</given-names></name><name><surname>Sibilia</surname><given-names>J</given-names></name><name><surname>Tebib</surname><given-names>J</given-names></name><etal/></person-group><article-title>Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: Data from a randomized, controlled, open-label trial</article-title><source>Arthritis Rheumatol</source><volume>66</volume><fpage>2015</fpage><lpage>2025</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/art.38671</pub-id><pub-id pub-id-type="pmid">24756903</pub-id></element-citation></ref>
<ref id="b3-mmr-17-03-4791"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Kawai</surname><given-names>S</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Miyasaka</surname><given-names>N</given-names></name></person-group><article-title>Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: A post hoc analysis of a double-blind, randomized, placebo-controlled study</article-title><source>Mod Rheumatol</source><volume>23</volume><fpage>1045</fpage><lpage>1052</lpage><year>2013</year><pub-id pub-id-type="doi">10.3109/s10165-012-0817-4</pub-id><pub-id pub-id-type="pmid">23271170</pub-id></element-citation></ref>
<ref id="b4-mmr-17-03-4791"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>JX</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>LN</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>XR</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Hao</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial</article-title><source>Medicine (Baltimore)</source><volume>95</volume><fpage>e3968</fpage><year>2016</year><pub-id pub-id-type="doi">10.1097/MD.0000000000003968</pub-id><pub-id pub-id-type="pmid">27428186</pub-id><pub-id pub-id-type="pmcid">4956780</pub-id></element-citation></ref>
<ref id="b5-mmr-17-03-4791"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name></person-group><article-title>Cucurbitacin E inhibits TNF-&#x03B1;-induced inflammatory cytokine production in human synoviocyte MH7A cells via suppression of PI3K/Akt/NF-&#x03BA;B pathways</article-title><source>Int Immunopharmacol</source><volume>29</volume><fpage>884</fpage><lpage>890</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.intimp.2015.08.026</pub-id><pub-id pub-id-type="pmid">26453509</pub-id></element-citation></ref>
<ref id="b6-mmr-17-03-4791"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>ML</given-names></name><name><surname>Ju</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Moon</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Min</surname><given-names>SY</given-names></name><name><surname>Cho</surname><given-names>YG</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Yoon</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Cyclosporine A inhibits IL-15-induced IL-17 production in CD4&#x002B; T cells via down-regulation of PI3K/Akt and NF-kappaB</article-title><source>Immunol Lett</source><volume>108</volume><fpage>88</fpage><lpage>96</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.imlet.2006.11.001</pub-id><pub-id pub-id-type="pmid">17161467</pub-id></element-citation></ref>
<ref id="b7-mmr-17-03-4791"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>XY</given-names></name><name><surname>Xia</surname><given-names>YF</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>ZF</given-names></name></person-group><article-title>Tetrandrine inhibits migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes through down-regulating the expressions of Rac1, Cdc42, and RhoA GTPases and activation of the PI3K/Akt and JNK signaling pathways</article-title><source>Chin J Nat Med</source><volume>13</volume><fpage>831</fpage><lpage>841</lpage><year>2015</year><pub-id pub-id-type="pmid">26614458</pub-id></element-citation></ref>
<ref id="b8-mmr-17-03-4791"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name></person-group><article-title>Combined therapeutic application of mTOR inhibitor and vitamin D(3) for inflammatory bone destruction of rheumatoid arthritis</article-title><source>Med Hypotheses</source><volume>79</volume><fpage>757</fpage><lpage>760</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.mehy.2012.08.022</pub-id><pub-id pub-id-type="pmid">22967804</pub-id></element-citation></ref>
<ref id="b9-mmr-17-03-4791"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>S</given-names></name></person-group><article-title>Gambogic acid inhibits Hsp90 and deregulates TNF-&#x03B1;/NF-&#x03BA;B in HeLa cells</article-title><source>Biochem Biophys Res Commun</source><volume>403</volume><fpage>282</fpage><lpage>287</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.11.018</pub-id><pub-id pub-id-type="pmid">21074517</pub-id></element-citation></ref>
<ref id="b10-mmr-17-03-4791"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palempalli</surname><given-names>UD</given-names></name><name><surname>Gandhi</surname><given-names>U</given-names></name><name><surname>Kalantari</surname><given-names>P</given-names></name><name><surname>Vunta</surname><given-names>H</given-names></name><name><surname>Arner</surname><given-names>RJ</given-names></name><name><surname>Narayan</surname><given-names>V</given-names></name><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Prabhu</surname><given-names>KS</given-names></name></person-group><article-title>Gambogic acid covalently modifies IkappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages</article-title><source>Biochem J</source><volume>419</volume><fpage>401</fpage><lpage>409</lpage><year>2009</year><pub-id pub-id-type="doi">10.1042/BJ20081482</pub-id><pub-id pub-id-type="pmid">19140805</pub-id><pub-id pub-id-type="pmcid">2741425</pub-id></element-citation></ref>
<ref id="b11-mmr-17-03-4791"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Gambogic acid inhibits the growth of ovarian cancer tumors by regulating p65 activity</article-title><source>Oncol Lett</source><volume>13</volume><fpage>384</fpage><lpage>388</lpage><year>2017</year><pub-id pub-id-type="doi">10.3892/ol.2016.5433</pub-id><pub-id pub-id-type="pmid">28123571</pub-id></element-citation></ref>
<ref id="b12-mmr-17-03-4791"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Gambogic acid protects from endotoxin shock by suppressing pro-inflammatory factors in vivo and in vitro</article-title><source>Inflamm Res</source><volume>62</volume><fpage>165</fpage><lpage>172</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s00011-012-0563-2</pub-id><pub-id pub-id-type="pmid">23064679</pub-id></element-citation></ref>
<ref id="b13-mmr-17-03-4791"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Qin</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name></person-group><article-title>Gambogic acid inhibits osteoclast formation and ovariectomy-induced osteoporosis by suppressing the JNK, p38 and Akt signalling pathways</article-title><source>Biochem J</source><volume>469</volume><fpage>399</fpage><lpage>408</lpage><year>2015</year><pub-id pub-id-type="doi">10.1042/BJ20150151</pub-id><pub-id pub-id-type="pmid">26205493</pub-id></element-citation></ref>
<ref id="b14-mmr-17-03-4791"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Noda</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Otani</surname><given-names>K</given-names></name><name><surname>Yoshiga</surname><given-names>M</given-names></name><name><surname>Oto</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Kurosaka</surname><given-names>D</given-names></name></person-group><article-title>Prokineticin 2 antagonist, PKRA7 suppresses arthritis in mice with collagen-induced arthritis</article-title><source>BMC Musculoskelet Disord</source><volume>17</volume><fpage>387</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s12891-016-1243-0</pub-id><pub-id pub-id-type="pmid">27609223</pub-id><pub-id pub-id-type="pmcid">5016855</pub-id></element-citation></ref>
<ref id="b15-mmr-17-03-4791"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Qiu</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Gambogic acid exhibits anti-psoriatic efficacy through inhibition of angiogenesis and inflammation</article-title><source>J Dermatol Sci</source><volume>74</volume><fpage>242</fpage><lpage>250</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.jdermsci.2014.03.001</pub-id><pub-id pub-id-type="pmid">24685902</pub-id></element-citation></ref>
<ref id="b16-mmr-17-03-4791"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lal</surname><given-names>P</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Holweg</surname><given-names>CT</given-names></name><name><surname>Silverman</surname><given-names>GJ</given-names></name><name><surname>Schwartzman</surname><given-names>S</given-names></name><name><surname>Kelman</surname><given-names>A</given-names></name><name><surname>Read</surname><given-names>S</given-names></name><name><surname>Spaniolo</surname><given-names>G</given-names></name><name><surname>Monroe</surname><given-names>JG</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name><name><surname>Townsend</surname><given-names>MJ</given-names></name></person-group><article-title>Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment</article-title><source>Arthritis Rheum</source><volume>63</volume><fpage>3681</fpage><lpage>3691</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/art.30596</pub-id><pub-id pub-id-type="pmid">22127691</pub-id></element-citation></ref>
<ref id="b17-mmr-17-03-4791"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>SC</given-names></name><name><surname>Welsing</surname><given-names>PM</given-names></name><name><surname>Jacobs</surname><given-names>JW</given-names></name><name><surname>van Laar</surname><given-names>JM</given-names></name><name><surname>Rensen</surname><given-names>WH</given-names></name><name><surname>Ardine de Wit</surname><given-names>G</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Lafeber</surname><given-names>FP</given-names></name></person-group><article-title>Economic evaluation of a tight-control treatment strategy using an imaging device (handscan) for monitoring joint inflammation in early rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><volume>33</volume><fpage>831</fpage><lpage>838</lpage><year>2015</year><pub-id pub-id-type="pmid">26343274</pub-id></element-citation></ref>
<ref id="b18-mmr-17-03-4791"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kullich</surname><given-names>WC</given-names></name><name><surname>Mur</surname><given-names>E</given-names></name><name><surname>Aglas</surname><given-names>F</given-names></name><name><surname>Niksic</surname><given-names>F</given-names></name><name><surname>Czerwenka</surname><given-names>C</given-names></name></person-group><article-title>Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><volume>24</volume><fpage>155</fpage><lpage>160</lpage><year>2006</year><pub-id pub-id-type="pmid">16762150</pub-id></element-citation></ref>
<ref id="b19-mmr-17-03-4791"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Baek</surname><given-names>SY</given-names></name><name><surname>Woo</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kwok</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group><article-title>Anthocyanin extracted from black soybean seed coats prevents autoimmune arthritis by suppressing the development of Th17 cells and synthesis of proinflammatory cytokines by such cells, via inhibition of NF-&#x03BA;B</article-title><source>PLoS One</source><volume>10</volume><fpage>e0138201</fpage><year>2015</year><pub-id pub-id-type="doi">10.1371/journal.pone.0138201</pub-id><pub-id pub-id-type="pmid">26544846</pub-id><pub-id pub-id-type="pmcid">4636296</pub-id></element-citation></ref>
<ref id="b20-mmr-17-03-4791"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XZ</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>SP</given-names></name><name><surname>Xu</surname><given-names>WD</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>XD</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>CG</given-names></name><name><surname>Shi</surname><given-names>YQ</given-names></name><etal/></person-group><article-title>Dishevelled2 promotes apoptosis and inhibits inflammatory cytokine secretion in rheumatoid arthritis fibroblast-like synoviocytes through crosstalk with the NF-&#x03BA;B pathway</article-title><source>Oncotarget</source><volume>8</volume><fpage>12649</fpage><lpage>12663</lpage><year>2017</year><pub-id pub-id-type="pmid">28187436</pub-id><pub-id pub-id-type="pmcid">5355042</pub-id></element-citation></ref>
<ref id="b21-mmr-17-03-4791"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>LM</given-names></name><name><surname>Xu</surname><given-names>JZ</given-names></name><name><surname>Tian</surname><given-names>K</given-names></name><name><surname>Gu</surname><given-names>CX</given-names></name><name><surname>Li</surname><given-names>ZF</given-names></name></person-group><article-title>Gastrodia elata attenuates inflammatory response by inhibiting the NF-&#x03BA;B pathway in rheumatoid arthritis fibroblast-like synoviocytes</article-title><source>Biomed Pharmacother</source><volume>85</volume><fpage>177</fpage><lpage>181</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.biopha.2016.11.136</pub-id><pub-id pub-id-type="pmid">27936399</pub-id></element-citation></ref>
<ref id="b22-mmr-17-03-4791"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ling</surname><given-names>H</given-names></name><name><surname>You</surname><given-names>QD</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name></person-group><article-title>Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis</article-title><source>J Mol Med (Berl)</source><volume>86</volume><fpage>1367</fpage><lpage>1377</lpage><year>2008</year><pub-id pub-id-type="doi">10.1007/s00109-008-0398-z</pub-id><pub-id pub-id-type="pmid">18777017</pub-id></element-citation></ref>
<ref id="b23-mmr-17-03-4791"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CH</given-names></name><name><surname>Xu</surname><given-names>LL</given-names></name><name><surname>Zhao</surname><given-names>JX</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>ZQ</given-names></name><name><surname>Deng</surname><given-names>XL</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Xing</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name></person-group><article-title>CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway</article-title><source>Inflamm Res</source><volume>65</volume><fpage>193</fpage><lpage>202</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s00011-015-0905-y</pub-id><pub-id pub-id-type="pmid">26621504</pub-id></element-citation></ref>
<ref id="b24-mmr-17-03-4791"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Park</surname><given-names>MK</given-names></name><name><surname>Cho</surname><given-names>ML</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Oh</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Heo</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name></person-group><article-title>Induction of macrophage migration inhibitory factor in ConA-stimulated rheumatoid arthritis synovial fibroblasts through the P38 map kinase-dependent signaling pathway</article-title><source>Korean J Intern Med</source><volume>25</volume><fpage>317</fpage><lpage>326</lpage><year>2010</year><pub-id pub-id-type="doi">10.3904/kjim.2010.25.3.317</pub-id><pub-id pub-id-type="pmid">20830230</pub-id><pub-id pub-id-type="pmcid">2932946</pub-id></element-citation></ref>
<ref id="b25-mmr-17-03-4791"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Anti-arthritic effects of clematichinenoside (AR-6) on PI3K/Akt signaling pathway and TNF-&#x03B1; associated with collagen-induced arthritis</article-title><source>Pharm Biol</source><volume>51</volume><fpage>13</fpage><lpage>22</lpage><year>2013</year><pub-id pub-id-type="doi">10.3109/13880209.2012.698287</pub-id><pub-id pub-id-type="pmid">22994412</pub-id></element-citation></ref>
<ref id="b26-mmr-17-03-4791"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>YF</given-names></name><name><surname>Xue</surname><given-names>YQ</given-names></name><name><surname>Fang</surname><given-names>LK</given-names></name><name><surname>Guo</surname><given-names>XH</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Mo</surname><given-names>BY</given-names></name><name><surname>Yang</surname><given-names>MR</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group><article-title>uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis</article-title><source>Cell Mol Immunol</source><month>Jan</month><day>16</day><year>2017</year><comment>(Epub ahead of print)</comment><pub-id pub-id-type="pmcid">5719144</pub-id></element-citation></ref>
<ref id="b27-mmr-17-03-4791"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>FL</given-names></name><name><surname>Xu</surname><given-names>RS</given-names></name><name><surname>Jiang</surname><given-names>DL</given-names></name><name><surname>He</surname><given-names>XL</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-&#x03BA;B and PI3K/Akt signaling pathways</article-title><source>Bone</source><volume>75</volume><fpage>128</fpage><lpage>137</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bone.2015.02.017</pub-id><pub-id pub-id-type="pmid">25708053</pub-id></element-citation></ref>
<ref id="b28-mmr-17-03-4791"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malemud</surname><given-names>CJ</given-names></name></person-group><article-title>The PI3K/Akt/PTEN/mTOR pathway: A fruitful target for inducing cell death in rheumatoid arthritis?</article-title><source>Future Med Chem</source><volume>7</volume><fpage>1137</fpage><lpage>1147</lpage><year>2015</year><pub-id pub-id-type="doi">10.4155/fmc.15.55</pub-id><pub-id pub-id-type="pmid">26132523</pub-id></element-citation></ref>
<ref id="b29-mmr-17-03-4791"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Raychaudhuri</surname><given-names>SK</given-names></name><name><surname>Raychaudhuri</surname><given-names>SP</given-names></name></person-group><article-title>IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade</article-title><source>Cytokine</source><volume>60</volume><fpage>38</fpage><lpage>42</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.cyto.2012.06.316</pub-id><pub-id pub-id-type="pmid">22840496</pub-id></element-citation></ref>
<ref id="b30-mmr-17-03-4791"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1&#x03B1;/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells</article-title><source>Cancer Sci</source><volume>105</volume><fpage>1063</fpage><lpage>1070</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/cas.12458</pub-id><pub-id pub-id-type="pmid">24890366</pub-id><pub-id pub-id-type="pmcid">4317858</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-17-03-4791" position="float">
<label>Figure 1.</label>
<caption><p>The structural formula of gambogic acid.</p></caption>
<graphic xlink:href="MMR-17-03-4791-g00.tif"/>
</fig>
<fig id="f2-mmr-17-03-4791" position="float">
<label>Figure 2.</label>
<caption><p>Gambogic acid decreased arthritis scores in RA mice. <sup>##</sup>P&#x003C;0.01 compared with Sham, &#x002A;&#x002A;P&#x003C;0.01 compared with RA model. RA, rheumatoid arthritis; Sham, sham control group; RA model, RA model group; GA, gambogic acid group.</p></caption>
<graphic xlink:href="MMR-17-03-4791-g01.tif"/>
</fig>
<fig id="f3-mmr-17-03-4791" position="float">
<label>Figure 3.</label>
<caption><p>Gambogic acid decreased TNF-&#x03B1;, IL-1&#x03B2;, IL-6 and IL-18 concentrations in RA mice. Gambogic acid decreased (A) IL-1&#x03B2;, (B) IL-6, (C) IL-18 and (D) TNF-&#x03B1;, concentrations in RA mice. <sup>##</sup>P&#x003C;0.01 compared with Sham, &#x002A;&#x002A;P&#x003C;0.01 compared with RA model. TNF, tumor necrosis factor; IL, interleukin; RA, rheumatoid arthritis; Sham, sham control group; RA model, RA model group; GA, gambogic acid group.</p></caption>
<graphic xlink:href="MMR-17-03-4791-g02.tif"/>
</fig>
<fig id="f4-mmr-17-03-4791" position="float">
<label>Figure 4.</label>
<caption><p>Gambogic acid decreased caspase-3 and caspase-9 activity in RA mice. Gambogic acid decreased (A) caspase-3 and (B) caspase-9 activity in RA mice. <sup>##</sup>P&#x003C;0.01 compared with Sham, &#x002A;&#x002A;P&#x003C;0.01 compared with RA model. RA, rheumatoid arthritis; Sham, sham control group; RA model, RA model group; GA, gambogic acid group.</p></caption>
<graphic xlink:href="MMR-17-03-4791-g03.tif"/>
</fig>
<fig id="f5-mmr-17-03-4791" position="float">
<label>Figure 5.</label>
<caption><p>Gambogic acid decreased MMP-2 and MMP-9 protein expression in RA mice. Gambogic acid decreased MMP-2 and MMP-9 protein expression by (A) western blot assays and (B and C) statistical analysis of MMP-2 and MMP-9 protein expression in RA mice. <sup>##</sup>P&#x003C;0.01 compared with Sham, &#x002A;&#x002A;P&#x003C;0.01 compared with RA model. MMP, matrix metalloproteinase; RA, rheumatoid arthritis; Sham, sham control group; RA model, RA model group; GA, gambogic acid group.</p></caption>
<graphic xlink:href="MMR-17-03-4791-g04.tif"/>
</fig>
<fig id="f6-mmr-17-03-4791" position="float">
<label>Figure 6.</label>
<caption><p>Gambogic acid decreased NF-&#x03BA;B and p-p38 protein expression in RA mice. Gambogic acid decreased NF-&#x03BA;B and p-p38 protein expression by (A) western blot assays and (B and C) statistical analysis of NF-&#x03BA;B and p-p38 protein expression in RA mice. <sup>##</sup>P&#x003C;0.01 compared with Sham, &#x002A;&#x002A;P&#x003C;0.01 compared with RA model. NF-&#x03BA;B, nuclear factor-&#x03BA;B; p-, phosphorylated; RA, rheumatoid arthritis; Sham, sham control group; RA model, RA model group; GA, gambogic acid group.</p></caption>
<graphic xlink:href="MMR-17-03-4791-g05.tif"/>
</fig>
<fig id="f7-mmr-17-03-4791" position="float">
<label>Figure 7.</label>
<caption><p>Gambogic acid increased TIMP-1, PI3K/Akt singnaling pathway in RA mice. Gambogic acid decreased TIMP-1, PI3K and p-Akt protein expression by (A) western blot assays and (B, C and D) statistical analysis of TIMP-1, PI3K and p-Akt protein expression in RA mice. <sup>##</sup>P&#x003C;0.01 compared with Sham, &#x002A;&#x002A;P&#x003C;0.01 compared with RA model. TIMP-1, tissue inhibitor of matrix metalloprotease-1; PI3K, phosphoinositide 3-kinase; RA, rheumatoid arthritis; p-, phosphorylated; Sham, sham control group; RA model, RA model group; GA, gambogic acid group.</p></caption>
<graphic xlink:href="MMR-17-03-4791-g06.tif"/>
</fig>
</floats-group>
</article>